The revenue increase was driven primarily by an increase in the sale of consumable test kits, and the firm added 75 commercially contracted instruments during Q1.
The company logged total Q1 revenues of $14.8 million, above its previous guidance of a revenue range of $13.4 million to $14.1 million.
The direct-to-consumer at-home health testing firm intends to use the funds to expands its platform development and supply logistics in North America.
The firm has three clinical trials in progress to validate the clinical utility of products it soon intends to submit for regulatory clearances to the FDA.
The firm said it has multiple point-of-care tests available in Brazil and anticipates soon fulfilling an order for its dengue, chikungunya, and Zika tests.
The firm said that it placed about 50 sample-to-answer molecular systems under contract during Q1, and it had about 625 active sample-to-answer product customers.
The upgrades include a method to connect Panther systems to create a higher-throughput system that can be configured to different footprints.
The company aims to launch a CE-IVD-marked MALDI system in 2021 that will identify bacteria in urinary tract infections without requiring sample culturing.
Its product revenues were up 30 percent year over year, but research revenues decreased 89 percent. The firm posted $329,000 in grant contribution revenues.
The firm said that its nucleic acid amplification test provides viral load measurements of HIV type 1 groups M/N and O, and HIV-2 within 70 minutes
The test for P. vivax-associated malaria was developed with support from FIND and will be distributed by Human Diagnostics Worldwide.
The developer of assays to detect drug-resistant strains of HIV has now branched into Lassa detection, and will potentially be seeking instrument partners.
The in vitro diagnostic is designed to detect whole gene segments for influenza A and B viruses and can characterize viruses as seasonal or nonseasonal.
Luminex has since fixed the problem with a software update but a similar issue with non-specific amplification has also affected two targets on BioFire's GI panel.
The company has split bloodstream infection testing into three multiplex panels that can detect a total of 56 pathogen targets and 10 markers of antimicrobial resistance.
The firm said its new molecular platform, which offers random-access testing, high throughput, and a broad menu has the potential to replace multiple instruments in molecular labs.
The firm said that the test, a hematology-based cellular biomarker that identifies morphological changes within monocyte white blood cells, could speed diagnosis.
The microfluidic immunoassay uses spectrometry and a lateral flow method to diagnose the "very large global health problem" in about 20 minutes.
The method, presented at the European Congress of Clinical Microbiology and Infectious Diseases, may provide results in hours rather than a week or more.
Industry executives said that clinical needs associated with antimicrobial resistance and sepsis are generating more interest in AST technologies.